Indiplon in the Management of Insomnia

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2009 Nov 19

PMID 19920929

Citations 3

Authors

Michael D Lemon

Joe D Strain

Annie M Hegg

Debra K Farver

Affiliations

Soon will be listed here.

Abstract

Indiplon is a novel pyrazolopyrimidine, nonbenzodiazepine gamma-aminobutyric acid (GABA) agonist studied for the treatment of insomnia. This article reviews the chemistry, pharmacology, clinical pharmacokinetics, drug interactions, clinical trials, safety, tolerability, contraindications, use in special populations, and dosing of indiplon. OVID, International Pharmaceutical Abstracts (IPA), and PubMed databases were searched (1966 to February 2009) for the keywords indiplon, NBI-34060, and insomnia. References of key articles were also reviewed to identify additional publications. Only English language articles were selected for review. Indiplon has been shown to have high affinity and selectivity for the GABAalpha(1) receptor subunit associated with sedation. In clinical studies, indiplon has demonstrated efficacy in improving latency to sleep onset, latency to persistent sleep, total sleep time, wake time after sleep onset, number of awakenings after sleep onset, and overall sleep quality when compared to placebo. Indiplon has a favorable safety profile with limited rebound insomnia and no tolerance. Neurocrine Biosciences, Incorporated received an Approvable Letter from the United States Food and Drug Administration in December 2007 for the indiplon IR 5 mg and 10 mg capsules based on meeting three additional requirements. At the time of this writing, indiplon remains unapproved.

Citing Articles

A Simple and Easily Implemented Method for the Regioselective Introduction of Deuterium into Azolo[1,5-]pyrimidines Molecules.

Danagulyan G, Panosyan H, Gharibyan V, Hasratyan A Molecules. 2023; 28(6).

PMID: 36985841 PMC: 10054722. DOI: 10.3390/molecules28062869.

Allosteric GABA Receptor Modulators-A Review on the Most Recent Heterocyclic Chemotypes and Their Synthetic Accessibility.

Vega Alanis B, Iorio M, Silva L, Bampali K, Ernst M, Schnurch M Molecules. 2020; 25(4).

PMID: 32102309 PMC: 7070463. DOI: 10.3390/molecules25040999.

Synthesis of New GABA Receptor Modulator with Pyrazolo[1,5-a]quinazoline (PQ) Scaffold.

Guerrini G, Vergelli C, Cantini N, Giovannoni M, Daniele S, Mascia M Int J Mol Sci. 2019; 20(6).

PMID: 30901916 PMC: 6470557. DOI: 10.3390/ijms20061438.

References

Barnard E, Skolnick P, Olsen R, Mohler H, Sieghart W, Biggio G . International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998; 50(2):291-313. View

Rosenberg R, Roth T, Scharf M, Lankford D, Farber R . Efficacy and tolerability of indiplon in transient insomnia. J Clin Sleep Med. 2007; 3(4):374-9. PMC: 1978303. View

Madan A, Fisher A, Jin L, Chapman D, Bozigian H . In vitro metabolism of indiplon and an assessment of its drug interaction potential. Xenobiotica. 2007; 37(7):736-52. DOI: 10.1080/00498250701433054. View

Farber R, Burke P . Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers. Curr Med Res Opin. 2008; 24(3):837-46. DOI: 10.1185/030079908X273327. View

Jhaveri M, Seal B, Pollack M, Wertz D . Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin. 2007; 23(6):1431-43. DOI: 10.1185/030079907X199619. View

Benca R . Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005; 56(3):332-43. DOI: 10.1176/appi.ps.56.3.332. View

Soldatos C, Dikeos D, Whitehead A . Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999; 14(5):287-303. View

Tyrer P, Murphy S, Riley P . The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord. 1990; 19(1):53-61. DOI: 10.1016/0165-0327(90)90009-w. View

Carter L, Griffiths R, Suess P, Casada J, Wallace C, Roache J . Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects. J Pharmacol Exp Ther. 2007; 322(2):749-59. DOI: 10.1124/jpet.107.119693. View

10.

. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2007; 22(2):1-30. View

11.

Morin A, Jarvis C, Lynch A . Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy. 2006; 27(1):89-110. DOI: 10.1592/phco.27.1.89. View

12.

Krystal A . The effect of insomnia definitions, terminology, and classifications on clinical practice. J Am Geriatr Soc. 2005; 53(7 Suppl):S258-63. DOI: 10.1111/j.1532-5415.2005.53391.x. View

13.

Walsh J . Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004; 65 Suppl 8:13-9. View

14.

Foster A, Pelleymounter M, Cullen M, Lewis D, Joppa M, Chen T . In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exp Ther. 2004; 311(2):547-59. DOI: 10.1124/jpet.103.063487. View

15.

Petroski R, Pomeroy J, Das R, Bowman H, Yang W, Chen A . Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther. 2006; 317(1):369-77. DOI: 10.1124/jpet.105.096701. View

16.

Sullivan S, Petroski R, Verge G, Gross R, Foster A, Grigoriadis D . Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. J Pharmacol Exp Ther. 2004; 311(2):537-46. DOI: 10.1124/jpet.104.071282. View

17.

Silber M . Clinical practice. Chronic insomnia. N Engl J Med. 2005; 353(8):803-10. DOI: 10.1056/NEJMcp043762. View

18.

Walsh J, Moscovitch A, Burke J, Farber R, Roth T . Efficacy and tolerability of indiplon in older adults with primary insomnia. Sleep Med. 2007; 8(7-8):753-9. DOI: 10.1016/j.sleep.2006.12.006. View

19.

Scharf M, Black J, Hull S, Landin R, Farber R . Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep. 2007; 30(6):743-52. PMC: 1978349. DOI: 10.1093/sleep/30.6.743. View

20.

Weitzel K, Wickman J, Augustin S, Strom J . Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin Ther. 2000; 22(11):1254-67. DOI: 10.1016/s0149-2918(00)83024-6. View